Navigation Links
Pharmacyclics Reports Financial Results for Fiscal 2010 and for Fourth Quarter 2010
Date:9/13/2010

hed that starting with cohort 2, PCI-32765 fully occupied the target kinase. Examining response in fully occupied dose cohorts the response rate ("RR") was 56% in the evaluable patient population and 48% in the ITT patient population. Including disease control in the form of stable disease in our assessment of evaluable patients, the disease control rate was 78% (10% CRs, 41% PRs and 27% SDs). Of note, the median tumor reduction from base line in our objective responding patients was 75% as of August 31, 2010.  
  • As of August 31, 2010, 23 patients continue to remain on study. This compares with 25 patients on study as of the ASCO presentation on June 4, 2010.  Median duration of response has not yet been determined in this ongoing study. The company has submitted an abstract describing the duration of response to the American Society of Hematology (ASH) in Orlando, FL on December 4-7, 2010; consistent with ASH's guidelines, we will not be disclosing these data prior to our ASH presentation.
  • PCI-32765 appears to be well tolerated through the initial exposure even in its highest dosing cohort (including 12.5 mg/kg). Only 2 patients of the enrolled 47 patients have experienced a dose limiting toxicity (DLT) on this trial (drug hypersensitivity and delay in dosing due to neutropenia for 7 days). No other DLTs have been observed. Thirteen of the 47 patients had 1 or more serious adverse events, but only 2 were considered drug related by investigators.
  • As previously announced we have initiated a Phase Ib trial in CLL/SLL patients studying 2 populations. One population is relapsed or refractory patients at 420 mg (24 patients with fixed dosing). The second population is elderly naive patients at 420 mg (12 patients with fixed dosing). Enrollment commenced end of May and as of to date we have dosed 30 patients (22/24 in the 420 mg relapsed or refractory dosed arm and 8/12 elderly naive patients). Amongst all patients dosed we maintain a ben
    '/>"/>

  • SOURCE Pharmacyclics
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14

    Related medicine technology :

    1. Pharmacyclics Announces Data and Publication Characterizing Highly-Selective HDAC Inhibitor
    2. Pharmacyclics Announces Preclinical Results Supporting Development of Its Novel Btk Inhibitor in Immune Mediated Diseases
    3. Pharmacyclics Reports Multiple Presentations at AACR on Its HDAC and Selective HDAC Inhibitors
    4. Pharmacyclics Novel Factor VIIa Inhibitor Demonstrates Potential Inhibition of Tumor Growth in Multiple Types of Cancer
    5. Pharmacyclics Novel Btk Inhibitor Shows Efficacy in Preclinical Models of Rheumatoid Arthritis and Lymphoma
    6. Pharmacyclics Announces Completion of Phase 1 Clinical Trial of Factor VIIa Inhibitor PCI-27483
    7. Pharmacyclics, Inc. Announces Closing of a Private Financing With the Principals of Pacific Biopharma Group, Ltd.
    8. Pharmacyclics Initiates Phase 1 Clinical Trial of Novel Oral Btk Inhibitor for Refractory B-cell Non-Hodgkins Lymphoma
    9. Pharmacyclics announces Global Strategic Alliance with Les Laboratoires Servier
    10. Pharmacyclics to Present at Merriman Curhan Fords Investor Summit 2009
    11. Pharmacyclics Announces Poster Presentations and Clinical Update at the 51st Annual Meeting of the American Society of Hematology
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:7/11/2014)... SAN DIEGO , July 11, 2014 ... Therapies Corp. ("Biotie") to end the option held by ... to commence further development of NRL-1 (intranasal diazepam) for ... seizures. Over the past year, Biotie has ... Neurelis in preparation for the pivotal clinical work required ...
    (Date:7/10/2014)... , 11. Juli 2014  Dilon ... für die molekulare Bildgebung, einschließlich molekularer ... die CE-Zulassung für sein Navigator ® ... Dilon das Produkt jetzt europaweit vertreiben. ... Großteil der europäischen Länder ausgedehnt und ...
    (Date:7/10/2014)... July 10, 2014  Breg, Inc., a premier ... launched the FreeRunner™ knee brace with new innovations ... patella mal-tracking return to active lifestyles.  FreeRunner,s patent-pending ... braces, providing support when patients need it most, ... don,t. Patellofemoral issues are the most ...
    Breaking Medicine Technology:Neurelis Regains Rights to Intranasal Diazepam Program 2Neurelis Regains Rights to Intranasal Diazepam Program 3Dilon erhält CE-Zulassung für sein Navigator-Gamma-Sondensystem 2Breg Introduces Knee Brace to Help Runners with Patellofemoral Pain Syndrome 2
    ... Dec. 17, 2010 The Penn Transplant Institute, the ... Surgery at the Hospital of the University of Pennsylvania ... Program. The Program will operate under the leadership of ... Gift of Life Donor Program, the nonprofit organ and ...
    ... Dec. 17, 2010 Accuray Incorporated (Nasdaq: ... radiosurgery, announced today that the company has established a ... and referral patterns and to provide strategic guidance on ... the company,s inception in 1990, Accuray has been focused ...
    Cached Medicine Technology:Penn Medicine Establishes Hand Transplant Program 2Penn Medicine Establishes Hand Transplant Program 3Penn Medicine Establishes Hand Transplant Program 4Penn Medicine Establishes Hand Transplant Program 5Accuray Establishes Medical Affairs Function 2Accuray Establishes Medical Affairs Function 3
    (Date:7/13/2014)... According to a new market research report ... (processor, GPU, DSP, connectivity), Technology Node (45nm-5nm), Application ... Forecast and Analysis to 2014-2020", published by MarketsandMarkets, ... is expected to reach $61.70 Billion by 2020, ... to 2020. , Browse 71 market data Tables ...
    (Date:7/13/2014)... 2014 The Pearland, Texas location of The ... from four months to 12 years of age that offers ... birthday parties and Summer Camps, is now under new ownership. ... Pearland after spending over six years at The Little ... Director. , Berry has over ten years of experience ...
    (Date:7/13/2014)... 13, 2014 Max International ... Mullin, will be the featured guest at its Charity ... Puerto Rico. Attendees will learn about Max’s health ... two exhibition basketball games and perform in a 3 ... of health- and energy-boosting supplements , has recently announced ...
    (Date:7/13/2014)... device developed at Cedars-Sinai can provide early detection ... and are a classic sign of Alzheimer,s disease, ... clinical trial in Australia. , The researchers will ... presentation at the Alzheimer,s Association International Conference 2014 ... conference organizers to participate in a "breaking news" ...
    (Date:7/13/2014)... A Xarelto lawsuit webpage has been launched ... with the most current information regarding serious internal bleeding ... as well as the growing number of Xarelto ... The law firm is now offering free legal evaluations ... bleeding and related complications while using Xarelto, including:, ...
    Breaking Medicine News(10 mins):Health News:Heterogeneous Mobile Processing & Computing Market Worth $61.70 Billion by 2020 – New Report by MarketsandMarkets 2Health News:Heterogeneous Mobile Processing & Computing Market Worth $61.70 Billion by 2020 – New Report by MarketsandMarkets 3Health News:Heterogeneous Mobile Processing & Computing Market Worth $61.70 Billion by 2020 – New Report by MarketsandMarkets 4Health News:The Little Gym of Pearland, TX Now Under New Ownership and Management 2Health News:Max International Announces NBA Dream Team Member Chris Mullin as Featured Guest of Charity Event 2Health News:Max International Announces NBA Dream Team Member Chris Mullin as Featured Guest of Charity Event 3Health News:Max International Announces NBA Dream Team Member Chris Mullin as Featured Guest of Charity Event 4Health News:Study of noninvasive retinal imaging device presented at Alzheimer's conference 2Health News:Study of noninvasive retinal imaging device presented at Alzheimer's conference 3Health News:Xeralto Lawsuit Page Launched By Wright & Schulte LLC To Provide Information On Potential For Xarelto Bleeding Side Effects, Growing Litigation 2Health News:Xeralto Lawsuit Page Launched By Wright & Schulte LLC To Provide Information On Potential For Xarelto Bleeding Side Effects, Growing Litigation 3Health News:Xeralto Lawsuit Page Launched By Wright & Schulte LLC To Provide Information On Potential For Xarelto Bleeding Side Effects, Growing Litigation 4
    ... First-ever Dr. Jacob Bolotin Awards to Be Presented ... The National Federation of,the Blind today launched the ... National Federation of the Blind will present cash ... contributions,toward achieving the full integration of the blind ...
    ... RARITAN, NJ, December 5 Jane Buckingham and ... Pill as part of The Modern,Girl,s Guide to the ... to the Pill, When: The Podcast will be ... http://feeds.feedburner.com/OrthoWomensHealthAndUrology , How: Go to the URL ...
    ... Dec. 5 HEI, Inc. (Nasdaq: HEII ),( ... Form 15 with the,Securities and Exchange Commission to voluntarily ... 1934. HEI expects that the,deregistration will be effective after ... application to deregister. As a result of this filing, ...
    ... the popularity of,fillers becoming mainstream, it,s no surprise ... facial wrinkles. Dr. Arnold Klein, world,renowned cosmetic dermatologist ... such as Artefill, Radiesse and Sculptra contain injectable,plexiglass, ... all of,these products can cause foreign body reactions," ...
    ... Montreal and Boston have identified a potential new ... is a common side-effect of anti-retroviral medications to ... the HIV Metabolic Clinic at the McGill University ... at the Massachusetts General Hospital Program in Nutritional ...
    ... the Annals,of Emergency Medicine ("Increasing Rates of Emergency Department ... 2003") finds the rate of,elderly Americans seeking emergency care ... L. Noller, MD, President of the American College of,Obstetricians ... behalf of the Alliance of Specialty Medicine., "While ...
    Cached Medicine News:Health News:National Federation of the Blind to Award $100,000 2Health News:HEI, Inc. Files Form 15 to Voluntarily Deregister its Shares With the SEC 2Health News:HEI, Inc. Files Form 15 to Voluntarily Deregister its Shares With the SEC 3Health News:Facial Deformity Danger? 2Health News:Major breakthrough toward the treatment of HIV/HAART-associated Lipodystrophy Syndrome 2Health News:Dramatic Growth Projected in Visits by Elderly Patients to Emergency Departments Underscores Urgency of Medicare Physician Payment Fix 2
    ... The pedicle screw insertion assembly incorporates ... and construct locking. The PathFinder MIS ... which the pedicle screw insertion assembly ... rod insertion. The evolutionary Pathfinder MIS ...
    Kerrison (Micro) Laminectomy Rongeur. 18 cm - 7 1/8, thick footplate, small handle, very delicate, 40 down-cutting, jaws 1 mm wide....
    Kerrison (Micro) Laminectomy rongeur with ejector. 18 cm - 7 1/8, thick footplate, small handle, very delicate, 40 up-cutting, jaws 2 mm wide....
    Regulates physiological flow within normal ranges of Intraventricular Pressure (IVP) in the supine, sitting or standing position....
    Medicine Products: